Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reported multiple insider acquisitions of equity tied to its October dividend reinvestment. Senior leaders and directors acquired Ordinary Shares on the London Stock Exchange and ADSs on the New York Stock Exchange through the Company’s Share Reward Plan and dividend reinvestment arrangements.
Examples include Emma Walmsley (CEO) acquiring 29 Ordinary Shares at £16.3921 and 105.836 at £16.4016 on 2025-10-09 (XLON). Other UK transactions occurred at £16.3921 or £16.4016 across small volumes by executives and PCAs. On the U.S. line, non-executive directors acquired ADSs at $43.7375 on 2025-10-10 (XNYS), including Charles Bancroft with 340 ADSs and Dr Vishal Sikka with 99 ADSs.
These entries reflect routine dividend reinvestments rather than open‑market discretionary purchases, documenting price and volume for each individual transaction and venue.
GSK plc reported a share buyback transaction conducted via BNP Paribas SA on 10 October 2025. The company purchased 355,000 ordinary shares of 31¼ pence each, paying between 1,623.00p and 1,646.00p per share, with a volume‑weighted average price of 1,635.50p. The shares will be held as Treasury shares under GSK’s existing buyback programme, executed under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has bought 2,904,000 ordinary shares. After this purchase, GSK holds 250,368,844 shares in treasury and has 4,065,044,985 ordinary shares in issue (excluding treasury), which is also the total number of voting rights. GSK confirmed the percentage of voting rights attributable to treasury shares is 6.16%. Aggregated by venue on the day: XLON 264,070 shares, CHIX 66,049, and BATE 24,881.
GSK plc filed a report showing several senior leaders acquiring small amounts of GSK ordinary shares through the company’s Share Reward Plan. On 2025-10-09, CEO Emma Walmsley acquired 14 ordinary shares (7 partnership and 7 matching shares) at £16.4083 per share on the London Stock Exchange. CFO Julie Brown, Group General Counsel James Ford, President Corporate Development David Redfern, President Global Supply Chain Regis Simard, President Global Affairs Philip Thomson, and ViiV Healthcare CEO and President Global Health Deborah Waterhouse each acquired 16 shares under the plan at the same price. SVP Global Communications Sally Jackson and SVP & Company Secretary Victoria Whyte each acquired 14 shares on the same terms.
GSK plc reports a share repurchase executed through BNP Paribas SA on
After this transaction GSK will hold 250,013,844 ordinary shares in treasury and will have 4,065,394,695 ordinary shares in issue (excluding treasury), which is also the company's total number of voting rights. The company states that ordinary shares held in treasury represent
GSK plc executed share repurchases on
GSK plc executed further purchases of its ordinary shares on
Since
GSK plc announced that, through BNP Paribas SA acting as broker, it purchased 340,000 ordinary shares of 31 1/4 pence each on
GSK plc executed purchases of its ordinary shares on Since
GSK plc disclosed a purchase of 335,000 ordinary shares on 02 October 2025 executed by BNP Paribas under its announced buyback programme. The announcement says the bought shares will be held as Treasury shares and that, since 30 September 2025, the Company has purchased a total of 902,000 ordinary shares.
Following this transaction the Company holds 248,366,844 ordinary shares in treasury and has 4,067,040,496 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,067,040,496 and the percentage of voting rights attributable to Treasury shares is 6.11%.
GSK plc reports that, acting through BNP Paribas SA, it purchased 262,000 ordinary shares of 31 3/4 pence each on 01 October 2025 as part of its existing buyback programme under the non-discretionary agreement announced on 30 September 2025. The announcement states that since 30 September 2025 the Company has purchased 567,000 ordinary shares. The purchased shares will be held as treasury shares. Following the purchase, GSK will hold 248,031,844 ordinary shares in treasury and will have 4,067,375,496 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,067,375,496, and the percentage of voting rights attributable to ordinary shares held in treasury is 6.10%. The filing includes a detailed schedule of individual trades executed on London exchanges and notes the purchase venues and aggregated trade information.